2013 REPORT ON THE STATE OF THE ART OF RARE DISEASE ACTIVITIES IN EUROPE

PART IV: EUROPEAN MEDICINES AGENCY ACTIVITIES AND OTHER EUROPEAN ACTIVITIES IN THE FIELD OF RARE DISEASES

This work was financed by the EUCERD Joint Action: Working for Rare Diseases N° 2011 22 01
This document has been produced by the Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD, formerly the European Commission’s Rare Diseases Task Force) through the EUCERD Joint Action: Working for Rare Diseases (N° 2011 22 01, Coordinator: Kate Bushby, University of Newcastle, United Kingdom), within the European Union’s Second Programme of Community Action in the Field of Health.

More information on the European Union Committee of Experts on Rare Diseases can be found at www.eucerd.eu.

Disclaimer:
The findings and conclusions in this report are those of the contributors and validating authorities, who are responsible for the contents; the findings and conclusions do not necessarily represent the views of the European Commission or national health authorities in Europe. Therefore, no statement in this report should be construed as an official position of the European Commission or a national health authority.

Copyright information:
The “2013 Report on the State of the Art of Rare Disease Activities" is copyrighted by the Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD). This product and its contents may be used and incorporated into other* materials on the condition that the contents are not changed in any way (including covers and front matter) and that no fee is charged by the reproducer of the product or its contents for their use. The product may not be sold for profit or incorporated into any profit-making venture without the expressed written permission of the EUCERD Scientific Secretariat. Specifically:

1) When the document is reprinted, it must be reprinted in its entirety without any changes.
2) When parts of the documents are used or quoted, the following citation should be used.

*Note: The “2013 Report on the State of the Art of Rare Disease Activities in Europe” contains material copyrighted by others. For material noted as copyrighted by others, the user must obtain permission from the copyright holders identified in the document.

To quote this document:


©European Union, 2013

Cover photo credit: Michel Depardieu ©Inserm
# CONTENTS

**GENERAL INTRODUCTION** ........................................................................................................................................................................... 5

**A. EUROPEAN MEDICINES AGENCY ACTIVITIES** ........................................................................................................................................... 10

1. The European Medicines Agency’s (EMA) activities in the field of orphan medicinal products and therapies for rare diseases ........................................................................................................................................ 10

2. EMA Committee for Orphan Medicinal Products’ (COMP) activities ........................................................................................................... 13

3. EMA Committee on Human Medicinal Products (CHMP) activities ........................................................................................................... 14

4. EMA activities in the field of clinical trials .................................................................................................................................................. 15

5. EMA activities in the field of advanced therapies ....................................................................................................................................... 16

6. EMA activities in the field of medicinal products for paediatric use ........................................................................................................ 18

7. Other EMA activities and initiatives relevant to rare diseases and orphan medicinal products ........................................................................ 19

8. International cooperation between regulators in the field of orphan medicinal products ........................................................................ 21

**B. OTHER EUROPEAN RARE DISEASE ACTIVITIES** ........................................................................................................................................... 24


2. E-Rare ................................................................................................................................................................................................. 24

3. Clinical genetics as a medical speciality .................................................................................................................................................. 25

4. Resolution on pharmacy prepared medicinal products adopted by the Council of Europe (2011) ................................................................. 25

5. International Rare Disease Events in 2012 ............................................................................................................................................... 26

6. Other European activities in the field of rare diseases in 2012 ........................................................................................................... 28

**SELECTED BIBLIOGRAPHY AND SOURCES** ........................................................................................................................................... 30
ACRONYMS

CAT - Committee for Advanced Therapies at EMA
CHMP - Committee for Medicinal Products for Human Use at EMA
COMP - Committee on Orphan Medicinal Products at EMA
DG - Directorate General
DG Enterprise - European Commission Directorate General Enterprise and Industry
DG Research - European Commission Directorate General Research
DG Sanco - European Commission Directorate General Health and Consumers
EC - European Commission
ECRD - European Conference on Rare Diseases
EEA - European Economic Area
EMA - European Medicines Agency
ERN - European reference network
EU - European Union
EUCERD - European Union Committee of Experts on Rare Diseases
EUROCAT - European surveillance of congenital anomalies
EUROPLAN - European Project for Rare Diseases National Plans Development
EURORDIS - European Organisation for Rare Diseases
FDA - US Food and Drug Administration
HLG - High Level Group for Health Services and Medical Care
HTA - Health Technology Assessment
IRDiRC – International Rare Diseases Research Consortium
JA - Joint Action
MA - Market Authorisation
MoH - Ministry of Health
MS - Member State
NBS - New born screening
NCA - National Competent Authorities
NHS - National Health System
PDCO - Paediatric Committee at EMA
RDTF - EC Rare Disease Task Force
WG - Working Group
WHO - World Health Organization
GENERAL INTRODUCTION

This document was produced by the Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD), through the EUCERD Joint Action: Working for Rare Diseases (N° 2011 22 01), which covers a three year period (March 2012 – February 2015).

The present report aims to provide an informative and descriptive overview of rare disease activities at European Union (EU) and Member State (MS) level in the field of rare diseases and orphan medicinal products up to the end of 2012. A range of stakeholders in each Member State/country have been consulted during the elaboration of the report, which has been validated as an accurate representation of activities at national level, to the best of their knowledge, by the Member State/country representatives of the European Union Committee of Experts on Rare Diseases. The reader, however, should bear in mind that the information provided is not exhaustive and is not an official position of the European Commission, its Agencies or national health authorities.

The report is split into six parts:

1. Overview of rare disease activities in Europe
2. Key developments in the field of rare diseases in 2012
3. European Commission activities in the field of rare diseases
4. European Medicines Agency activities and other European activities in the field of rare diseases
5. Activities in EU Member States and other European countries in the field of rare diseases
6. Activities at National level in each EU Member State and other European countries in the field of rare diseases

Each part contains the following description of the methodology, sources and validation process of the entire report, and concludes with a selected bibliography and list of persons having contributed to the report.

1. METHODOLOGY AND SOURCES

The main sources of data for the update of the present report were those collected through the systematic surveillance of international literature and the systematic query of key stakeholders carried out in order to produce the OrphaNews Europe newsletter, various reports published by the European Commission (including past reports of the workshops of the EUCERD) and other specialised reports on topics concerning the field of rare diseases and orphan medicinal products. The principal information sources and the collection of data are described in detail here below.

- **European Commission websites and documents**
  Information and documentation from the European Commission was used in order to establish this report, principally accessed through the rare disease information web pages of the Directorate General Public Health\(^1\) and Directorate General Research CORDIS website\(^2\) as well as the site of the European Medicines Agency\(^3\), in particular the pages of the COMP\(^4\) (Committee of Orphan Medicinal Products).

- **OrphaNews Europe**
  Data from the OrphaNews Europe\(^5\) newsletter for the 2012 period was reviewed and analysed in order to identify initiatives, incentives and developments in the field of rare diseases. The data chosen for analysis and inclusion in the report is mainly information concerning actions of the Commission in the

---

\(^3\) [www.ema.europa.eu](http://www.ema.europa.eu)
\(^5\) [http://www.orpha.net/actor/cgi-bin/OAhome.php?Ltr=EuropeNews](http://www.orpha.net/actor/cgi-bin/OAhome.php?Ltr=EuropeNews)
field of rare diseases, the development of rare disease focused projects funded by the Commission and other bodies, and developments in the field of rare diseases at MS level (in particular data concerning the development of national plans and strategies for rare diseases). A similar analysis of the French language newsletter OrphaNews France⁶ (which focuses particularly on developments in the field of rare diseases in France) was carried out in order to collect information for the section concerning France.

- **EUCERD Publications**
  Parts III, IV and V of this report present an update of the information previously published in the 2009 Report on initiatives and incentives in the field of rare diseases of the EUCERD⁷ (July 2010), 2011 EUCERD Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases⁸ and the 2012 EUCERD Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases⁹. The methodology for the production of these previous reports is outlined in their respective introductions. In addition, reports from previous workshops of the EUCERD, including the EUCERD Joint Action have been used.

- **Reports of the EUCERD meetings**
  The reports of 2012 meetings of the EUCERD were used in order to identify upcoming initiatives and incentives in the field of rare diseases, and to report on the events held to mark Rare Disease Day 2011.

- **Reports on orphan medicinal products**
  The information provided for each Member State concerning the state of affairs in the field of orphan medicinal products has been elaborated, when referenced, from the basis of the 2005 revision of the Inventory of Community and Member States' incentive measures to aid the research, marketing, development and availability of orphan medicinal products¹⁰ published in 2006 by the European Commission and produced using data collected by the EMA and Orphanet. This information has been updated when information is available and quoted when still applicable. Another valuable source of information on Orphan Drug policy, at EU and Member State levels was the 2009 KCE 112B report published by the KCE-Belgian Federal Centre of Healthcare Expertise (Federaal Kenniscentrum voor de Gezondheidszorg/Centre federal d'expertise des soins de santé) entitled “Orphan Disease and Orphan Drug Policies” (Politiques relatives aux maladies orphelines et aux médicaments orphelins)¹¹. This report notably provided information for the Member State sections on Belgium, France, Italy, the Netherlands, Sweden and the United Kingdom. The Office of Health Economics Briefing Document “Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries (No. 52 October 2009)” also provided information on orphan medicinal product availability and reimbursement for the Member State sections on France, Germany, Italy, Spain, Sweden, the Netherlands and the United Kingdom. Further detail for Part V was added to the 2012 edition thanks to the JustPharma report Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition¹² by Donald Macarthur: this report is referenced in footnotes when used.

- **EURORDIS website and websites of national alliances of patient organisation**
  The site of EURORDIS, the European Organisation for Rare Diseases¹³ was used to provide information on EURORDIS activities and projects and to collect data concerning umbrella patient organisations in

---

⁶ [http://www.orpha.net/actor/cgi-bin/OAHome.php](http://www.orpha.net/actor/cgi-bin/OAHome.php)
Each of the European Member States and country-level rare disease events. The websites of national patient alliances were also consulted for information. In addition to this the Rare Disease Day 2012 site\textsuperscript{14}, maintained by EURORDIS, also provided information on events at Member State level\textsuperscript{15} concerning Rare Disease Day.

- **Orphanet**
  The Orphanet database was consulted to retrieve data on centres of expertise and the number of genes and diseases tested at Member State level, as well as specific information concerning rare disease research projects, registries, clinical trials, patient organisations and rare disease/orphan medicinal product policies outside of Europe for Part I. Orphanet also provides links\textsuperscript{16} to other web-based information services and helplines which were used to collect information at country-level. The Orphanet Country Coordinators also provided valuable input into the elaboration of information at country level, notably via contributions to OrphaNetWork News. The national Orphanet websites were also consulted to gather national events and initiatives.

A selected bibliography and contributions are provided at the end of each volume of the report.

### 2. REPORT PREPARATION, REVISION AND VALIDATION

The present report provides an updated compilation of information from the previous reports of the EUCERD on the state of the art of rare diseases activities in Europe (2009 Report on initiatives and incentives in the field of rare diseases of the European Union Committee of Experts on Rare Diseases, 2011 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases and 2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases) which have covered activities up to the end of 2011. The present edition takes into account advances and activities in the field of rare diseases and orphan medicinal products at EU and MS level in 2012.

Once this information from the previous report was updated using the sources cited above, a draft of each country section (Part V) was sent in February 2013 to EUCERD Member States representatives with a guidance document providing an explanation of the type of information to include if available for each category. The Member State representatives were asked to contact a range of identified key stakeholders in their country for input. The stakeholders identified for each country included: representatives at the EUCERD in the respective countries and their alternates, the Orphanet Country Coordinators, National Alliances of rare disease patient alliances, partners of the E-Rare consortium, Member State representatives on the COMP, representatives of national competent authorities, coordinators of national plans for rare diseases and other rare diseases experts identified at national level. The Member State representatives integrated the stakeholder feedback into their report before returning it to the Scientific Secretariat for homogenisation and extraction of developments in 2012 to be included in Part II. Final validation of Parts II, V, VI concerning their country were sent to the EUCERD Member State representatives for final validation, to the best of their knowledge, in May 2013.

Part III and IV of the report on activities at European Union level was sent for validation, to the best of their ability, by the representatives at the EUCERD of the European Commission Directorate Generals for Health and Consumers, Research and Innovation, Enterprise and Industry, and the European Medicines Agency (EMA) respectively: this process was carried out in March/April 2013 by the Scientific Secretariat of the EUCERD. The European Commission and its agencies are not responsible, however, for the completeness and the accuracy of the information presented in this report. The new activities in 2012 were extracted and added to Part II.

Part I was the final volume of the report to be elaborated: the overview of the state of the art of rare disease activities in Europe is the result of an analysis of the information collected for Parts II, III, IV and V. Part I was

\textsuperscript{14} http://www.rarediseaseday.org/
\textsuperscript{15} http://www.rarediseaseday.org/country/finder
\textsuperscript{16} http://www.orpha.net/consor/cgi-bin/Directory_Contact.php?lng=EN
3. REPORT STRUCTURE

The report is structured into three main parts: Part I consists of an overview of the activities in the field of rare diseases in Europe at EU and MS level; Part II is an extraction of the developments at EU and MS level in 2012 based on Parts III, IV and V; Part III concerns activities of the European Commission; Part IV concerns European Medicines Agency activities and other European activities/events at European level apart from the activities of the European Commission; Part V concerns activities at EU MS level, as well as five other non-EU European countries where information was available; Part V provides the content of Parts II and V in individual country-specific reports.

Each part is followed by a selected bibliography outlining the sources used to produce that part of the report, which includes a list of the European Commission documents referred to in the report and a list of web addresses by country listing national sources of information on rare diseases and links to documents concerning national plans or strategies for rare diseases when in place. Each part is also followed by is a list of contributors the report, organised by country with mention of the validating authority in each country, and stating their contribution to the current and/or previous report. A list of frequently used acronyms has also been included in each part to ease reading.

Part I provides an overview of the state of the art of rare disease activities in the field of rare diseases in Europe at EU and MS level. This part thus serves as a summary to highlight key areas of the Parts III, IV and V, which serve to provide more detailed background information at EU and MS level. The overview is structured into a number of topics: political framework, expert services in Europe, research and development, orphan medicinal products and therapies for rare diseases, patient organisations and information services.

Part II is a new section of the report, providing information extracted from Parts III, IV and V, relative only to the new activities and initiatives reported for the year 2012.

Part III of the report focuses on activities in the field of rare diseases at EC level is split into four sub-sections:
1. EC activities related to rare diseases in the field of public health;
2. EC activities related to rare diseases in the field of research;
3. EC activities in the field of orphan medicinal products and therapies for rare diseases.

The sub-section concerning the EC activities actions in the area of Public Health is divided into three parts: an overview of DG Health and Consumers’ activities in the field of public health, activities in the field of rare diseases funded by DG Health and Consumers, and activities of DG Health and Consumers indirectly related to rare diseases. The sub-section concerning the EC activities in the field related to research in the field of rare diseases presents information concerning DG Research and Innovation’s 5th, 6th and 7th framework programmes for research, technological development and demonstration activities related to rare diseases, as well as information concerning the International Rare Disease Research Consortium (IRDiRC).

Part IV of the report contains information on the activities in the field of rare diseases of the EMA and other rare disease activities at the European level, including selected transversal EU activities and conferences at European level:

- European Medicine Agency’s (EMA) activities in the field of orphan medicinal products and therapies for rare diseases, EMA Committee for Orphan Medicinal Products’ activities, EMA Committee on Human Medicinal Products’ activities, European legislation and activities in the field of clinical trials, European legislation and activities in the field of advanced therapies, European legislation and activities in the field of medicinal products for paediatric use, other EMA activities and initiatives relevant to rare diseases and orphan medicinal products, EU-USA collaboration in the field of orphan medicinal products and other EC activities and initiatives in the field of orphan medicinal products.
The sub-section concerning other European rare disease activities provides information on transversal rare disease activities and initiatives at EU level and includes information on the High Level Pharmaceutical Forum, actions undertaken in the scope of recent European Union presidencies, the E-Rare ERA-Net for rare diseases and outcomes of European and International rare disease congresses and conferences in 2012.

**Part V** concerns the rare disease activities in the field of rare diseases in each of the 27 Member States plus Iceland, Norway and Switzerland in addition to Croatia and Turkey as candidates for EU membership, as well as Israel. These sections are organised in alphabetical order by country.

The information on each country is clearly divided into a number of categories:

- Definition of a rare disease
- National plan/strategy for rare diseases and related actions
- Centres of expertise
- Registries
- Neonatal screening policy
- Genetic testing
- National alliances of patient organisations and patient representation;
- Sources of information on rare diseases and national help lines
- Good practice guidelines
- Training and education initiatives
- National rare disease events in 2012
- Hosted rare disease events in 2012
- Research activities (National research activities, Participation in European research projects, Participation in E-Rare, Participation in IRDiRC)
- Orphan medicinal products (Orphan medicinal product committee, Orphan medicinal product incentives, Orphan medicinal product availability, Orphan medicinal product pricing policy, Orphan medicinal product reimbursement policy, Other initiatives to improve access to orphan medicinal products), Other therapies for rare diseases
- Orphan devices
- Specialised social services

The categories for which information is provided depend wholly on the information available following data collection from the described sources and contact with stakeholders. If no detail has been given for a topic, the mention “no specific activity/information reported” has been added.

**Part VI** concerns the rare disease activities in the field of rare diseases in each of the 27 Member States plus Iceland, Norway and Switzerland in addition to Croatia and Turkey as candidates for EU membership, as well as Israel. This section is the same as Parts II and V, except that the information is presented as a separate document for each country to facilitate dissemination at country level.

Each section has two parts: firstly the state of the art up until the end of 2012, and secondly the state of the art of activities in 2012 only so as to easily identify new actions and activities.

---

17 The term “official centre of expertise” used in this report means officially designated via a (ministerial) procedure.

18 This section contains data extracted in December 2012 from the Orphanet database of the number of genes for which there is a diagnostic test registered in Orphanet and the estimated number of diseases for which diagnostic tests are registered in Orphanet (the term ‘estimated’ is used as the concept of a single disease is a variable one).

19 As announced in OrphaNews Europe.

20 As announced in OrphaNews Europe.

21 Past and ongoing participation in DG Research and Innovation financed projects. Some countries have added information on additional European projects.

22 Contacts were asked to provide information on availability of orphan medicinal products (i.e. which drugs are launched on the market/sold at national level). As this information is often hard to identify, some countries instead provided information on which drugs are accessible (i.e. reimbursed, on a positive drug list etc.). It is explicitly explained in each case which of these concepts is being referred to.
A. EUROPEAN MEDICINES AGENCY ACTIVITIES

1. The European Medicines Agency’s (EMA) activities in the field of orphan medicinal products and therapies for rare diseases

European Medicines Agency

The European Medicines Agency (EMA) is a decentralised body of the European Union, located in London. Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use.

The Agency is responsible for the scientific evaluation of applications for European marketing authorisations for both human and veterinary medicines (centralised procedure). Under the centralised procedure, companies submit a single marketing-authorisation application to the Agency. Once granted by the European Commission, a centralised (or ‘Community’) marketing authorisation is valid in all European Union (EU) and EEA-EFTA states (Iceland, Liechtenstein and Norway). All medicines for human and animal use derived from biotechnology and other high-tech processes must be approved via the centralised procedure. The same applies to all advanced-therapy medicines and human medicines intended for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases, as well as to all designated orphan medicines intended for the treatment of rare diseases.

The Agency constantly monitors the safety of medicines through a pharmacovigilance network, and takes appropriate actions if adverse drug reaction reports suggest that the benefit-risk balance of a medicine has changed since it was authorised.

The Agency also plays a role in stimulating innovation and research in the pharmaceutical sector. The Agency gives scientific advice and other assistance to companies for the development of new medicines. It publishes guidelines on quality-, safety- and efficacy-testing requirements. A dedicated SME Office, established in 2005, provides special assistance to small and medium-sized enterprises.

Seven scientific committees, composed of members of all EU and EEA-EFTA states, some including patients’ and doctors’ representatives, conduct the main scientific work of the Agency: the Committee for Medicinal Products for Human Use (CHMP), the Committee for Medicinal Products for Veterinary Use (CVMP), the Committee for Orphan Medicinal Products (COMP), the Committee on Herbal Medicinal Products (HMPC), the Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT), and the Pharmacovigilance Risk Assessment Committee (PRAC). The PRAC started working in 2012 and it is the last Committee being created at the Agency; and is responsible for providing recommendations to the Committee for Medicinal Products for Human Use and the coordination group on any question relating to pharmacovigilance activities in respect of medicinal products for human use and on risk management systems and monitoring the effectiveness of those risk management systems.

The Agency works with a network of over 4,500 ‘European experts’, who serve as members of the Agency’s scientific committees, working parties or scientific assessment teams. These experts are made available to the Agency by the national competent authorities of the EU and EFTA states.

The Agency can be considered as the ‘hub’ of a European medicines network comprising over 40 national competent authorities in 30 EU and EEA-EFTA countries, the European Commission, the European

27 http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000217.jsp&murl=menus/about_us/about_us.jsp&mid=WCO01ac05800028c77
Parliament and a number of other decentralised EU agencies. The Agency works closely with its European partners to build the best possible regulatory system for medicines for Europe and protect the health of its citizens.

In view of the continuing globalisation of the pharmaceutical sector, the Agency works to forge close ties with partner organisations around the world, including the World Health Organization and the regulatory authorities of non-European nations. The Agency is continually involved in a wide range of cooperation activities with its international partners, designed to foster the timely exchange of regulatory and scientific expertise and development of best practices in the regulatory field.

The Agency is also involved in referral or arbitration procedures relating to medicines that are approved or under consideration by Member States in non-centralised authorisation procedures.

Work programme

The European Medicines Agency’s Management Board, at its meeting on 15 December 2011, adopted the Agency’s work programme and budget for 2012 which are driven by the implementation of the pharmacovigilance legislation. The work programme forecasted a stable number of applications for marketing authorisation for human and veterinary medicines in 2012. The Agency expected some 112 applications in total (2011: 111), with 52 applications for new medicines for human use, in addition to 13 new orphan medicines and 39 generic applications (2011: 47, 13 and 45 respectively). The Board noted the 10% increase in expected requests for scientific advice for human medicines, which includes an increasing number of joint scientific advices with health technology assessment bodies (HTAs). New pharmacovigilance legislation, implementing revised policies on handling of conflicts of interests and ethical and good clinical practice (GCP) aspects of clinical trials, progress of Agency interaction with healthcare professionals, supply shortages of medicines caused by insufficient good manufacturing practice (GMP) compliance, were all listed as priority areas in the work plan.

In the document it was noted that orphan medicinal product designations were expected to increase steadily in number and complexity as a consequence of the incentives for development and marketing of advanced therapies and innovative products for disease subsets. Continued collaboration with the FDA on joint designation assessment was also expected. Objectives for 2012 included the development of a pilot project on orphan medicines to explore how to better communicate and justify significant-benefit decisions reached by the Committee for Orphan Medicinal Products (road map initiative), a review of orphan medicines development to identify bottlenecks in development and provide feedback for the EU research policy on rare diseases, and the identification of advanced therapy medicinal products (ATMPs) designated as orphan medicinal products and their specific regulatory needs.

The European Medicines Agency’s Management Board, at its meeting on 13 December 2012, adopted the Agency’s work programme and budget for 2013. The Agency’s priorities will be to continue to ensure that assessment activities are conducted to the highest scientific levels, to increase efficiency in its activities, and to develop initiatives for greater transparency and communication with stakeholders. Further specific drivers include the continued implementation of the pharmacovigilance legislation and the new falsified-medicines legislation, and the planned revision of the veterinary medicines legislation. In 2013, the Agency expects a stable total number of applications for human medicines, with 100 applications in 2013. These include some 54 applications for new medicinal products (excluding designated orphan medicines), 20 new orphan medicines and 20 generic applications (2012: 52, 13 and 39 respectively). Some 10 applications for new veterinary medicines are expected, with 3 generic applications (2012: 9 and 3 respectively). The work programme is accompanied by a budget of €231.6 million, an increase of 4.1% over 2012, which includes fee revenue of €179.8 million (3.8% increase compared with 2012, this increase is mainly due to inflation) and a European Union (EU) contribution of €39.2 million.

During 2013 the Agency will continue to foster its approach to communication and transparency in order to strengthen public confidence in the Agency and the EU system of evaluation and supervision of medicines. The publication of the agendas and minutes of all scientific committees’ meetings has been already

a reality for the Committee for Orphan Medicinal Products since September 2012. Following the successful workshop in November 2012 on access to clinical-trial data and transparency, the Agency will start a consultation with stakeholders at the beginning of 2013 in order to publish a policy on the release of data from clinical trials in early 2014.

**EMA Road Map to 2015**
In late 2010, the EMA’s Management Board adopted the new Road Map to 2015 that takes into account the public consultation26 held in the first half of 2010 that brought responses from “EU institutions, Member States, and organisations representing patients and consumers, healthcare professionals, pharmaceutical industry, academia and health technology assessment bodies”. The new plan builds upon the accomplishments made from the objectives of the 2005-2010 strategy and continues to focus on the “high-quality delivery of the Agency’s core business in an increasingly complex regulatory and scientific environment”. In the new plan, three priority areas have been identified: Addressing public health, Facilitating access to medicines, and Optimising the safe use of medicines. The proposed vision also specifies that “another aspect which will remain high on the public health agenda relates to the availability of medicines for rare diseases and other current unmet medical needs such as medicines for the paediatric population”. Particularly relevant to rare diseases, Strategic Area 1 includes amongst its objectives the stimulation of medicine development in the areas of unmet medical needs, including rare disorders. To address the challenge of existing gaps in medicine development, the EMA proposes undertaking an analysis of “the reasons for discontinuation of the development of medicines for human use starting with selected designated orphan medicines and propose remedial action. Any solution should favour a holistic approach, including the use of novel endpoints, different study designs and a more appropriate use of the accelerated assessment scheme for medicines intended for unmet medical needs, rare diseases and neglected diseases in the EU and beyond”.

The final Road Map was published in January 201127 and detailed information on the implementation of the road map was provided in the document ‘From vision to reality’28.

**EMA annual reports**
The European Medicines Agency Annual Report for 201129 was released in mid 2012. The report shows continuously high levels of activities in almost all of the Agency’s business areas. There was a slight increase in the number of applications for initial marketing authorisations for medicines for human use, from 91 applications in 2010 to 100 applications in 2011. Most of this increase was due to applications received for new medicines: this number rose by over 40% from 34 in 2010 to 48 in 2011. The number of applications received for initial marketing authorisation for veterinary medicines declined slightly, which is likely to reflect the delayed impact of global recession and the consolidation seen in recent years in the veterinary sector. Significant advances were made in terms of transparency. In March 2011, the European Union Clinical Trials Register went live. The launch of this database was welcomed by patients’, consumers’ and healthcare professionals’ organisations as an important step towards increasing transparency of medical research and facilitating availability of information about clinical trials taking place. Later in the year, the Agency launched a new database of European experts, which allows the public to access an expert’s declaration of interests online. However, nowhere was the impact of the Agency’s much more proactive approach to transparency more dramatic as in relation to handling of access-to-documents requests. During the course of the first full year of operation of the new access to documents policy, the Agency released more than a million pages in response to requests.

In 2011 the EMA received 166 orphan designation applications, of which 111 positive opinions were issued by the Committee for Orphan Medicine Products (COMP). Of these, oncology products once again were in the majority.

**Reduced fees for designated orphan medicinal products**
As of 1 February 2009, designated orphan medicinal products are eligible for reductions for all fees payable under Community rules pursuant to amended Regulation (EEC) 2309/93. The EMA revised the fee reduction policy in April 2011 to ensure adequate incentives are still offered with the EU contribution received for 2011. The revised policy was adopted with an aim to ensuring that incentives for Small and Medium-sized Enterprises

---

(SMEs) developing orphan medicinal products are maintained at the same level as previous years. In order to keep this objective the fee reductions for bigger pharmaceutical companies have been decreased.

Incentives for SMEs foreseen in 2013
The European Medicines Agency (EMA) has continually provided incentives to micro, small and medium size enterprises to support them in the development of orphan medicines. In a welcome decision by the EMA, these SMEs can continue to avail in 2013 the free services of protocol assistance (scientific advice); fee waiver for initial market-authorisation applications, pre-authorisation inspections, post-authorisation applications and annual fee waiver in the first year from marketing authorisation. However, Non-SMEs developing orphan medicinal products will have fewer benefits in 2013 in some categories. Fee reductions for non-SME will now include a 40% reduction for non-paediatric protocol assistance (previously 75%) and no fee reductions for initial market-authorisation applications (previously 10%) and pre-authorisation inspections (previously 100%). Protocol assistance for paediatric-related medicines will continue to be free for non-SME.

2. EMA Committee for Orphan Medicinal Products’ (COMP) activities

EMA Committee for Orphan Medicinal Products (COMP)
Since 2000, there is a Committee for Orphan Medicinal Products38 (COMP) at the European Medicines Agency (EMA). The COMP is comprised of health professionals representing each of the Member States, three patient representatives, and three other representatives nominated by the EC after recommendation from the EMA. The Committee meets once a month and it is responsible for reviewing applications from persons or companies seeking ‘orphan medicinal product designation’ for products they intend to develop for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons in the European Union. The Commission adopts decisions on designation based on an opinion from the COMP. The EMA maintains a searchable list of opinions on rare disease (orphan) designations39. The full list of orphan designations granted by the European Commission is available in the Community register of orphan medicinal products for human use held by the European Commission40. The COMP is also responsible for advising the European Commission on the establishment and development of a policy on orphan medicinal products in the EU, and assists the Commission in drawing up detailed guidelines and liaising internationally on matters relating to orphan medicinal products.

The development of orphan medicinal products is supported by incentives for development and placement on the market as provided for in the Orphan Regulation. The Scientific Advice Working Party in collaboration with the COMP offers protocol assistance to provide advice on the development of orphan medicinal products with regards to regulatory, quality, safety and efficacy issues. Protocol assistance activities have been increasing in number since its establishment.

The COMP is presently chaired by Bruno Sepodes (Portugal) and co-chaired by Lesley Greene (Patient Representative, UK). The COMP was a pioneer in including patient representatives as full members and the experience has illustrated the great added-value of this collaboration, which contributes to the quality of the opinions adopted for orphan designation.

Since its implementation, the Orphan Regulation has yielded more than 1120 positive opinions for orphan product designation, adopted from 1630 applications reviewed since 2000. To date, the distribution of the prevalence of conditions for which the designations have been adopted shows that the most frequently designated conditions have been those that affect between 1 and 3 in 10 000 patients, that is between approximately 50 000 and 150 000 people (receiving 51% of all orphan designations). Indeed, 48% of the orphan medicinal products having obtained market authorisation in the EU, are for the treatment of diseases affecting less than 1 in 10 000 patients.

The number of applications has increased steadily each year during the first decade of the Regulation with 197 applications received in 2012. Seventy-eight designated products had received marketing authorisation by the end of 2012, of which oncology is by far the most common therapeutic area (39%).

38This section reproduces information from http://www.ema.europa.eu/htms/general/contacts/COMP/COMP.html
Interestingly, the average time span between designation and authorisation is only 2.8 years, indicating that designated products were at an advanced developmental stage.

The COMP has also granted orphan medicinal product designations to various innovative product types (i.e. fusion proteins, monoclonal antibodies, cell and gene therapy products, tissue-engineered products, oligonucleotides): at the end of 2012, the COMP has given more than 80 positive opinions for advanced therapy products out of a total of 1125 positive opinions for orphan medicinal product designation.

Positive opinions on orphan designations in 2012
The COMP adopted 139 positive opinions on orphan designations in 2012. The European Commission granted 148 of orphan designations in 2012. Ten orphan medicinal products received marketing authorisation in 2012 covering 12 conditions (due to variations)\(^\text{41}\).

**EMA’s Committee for Orphan Medicinal Products initiative to publish prevalence information (2012)**

As part of a general growing trend toward sharing data and resources in the interest of facilitating rare disease and orphan drug information and research, the European Medicines Agency (EMA) has created a table of relevant sources for prevalence data for orphan conditions\(^\text{42}\). The sources included in the document were validated by the Committee for Orphan Medicinal Products (COMP) during the evaluation of orphan designation applications. The table, publicly available, will be updated on a regular basis. While sponsors are still required to submit original, verifiable, current prevalence data with their application for an orphan designation, the table is considered a useful resource for facilitating access to such data. Orphan designated medicinal products are indicated for conditions that affect 5 persons or less per 10 000 of the population in the EU. Determining prevalence can be challenging for stakeholders. The new table lists the sources, such as relevant scientific literature, registries and databases, used to determine prevalence for a condition at the time an orphan designation was sought.

### 3. EMA Committee on Human Medicinal Products (CHMP) activities

**EMA Committee on Human Medicinal Products (CHMP) and compassionate use**

Before a medicinal product can be marketed in the European Union (EU) by a pharmaceutical company, the product must receive a marketing authorisation. However, for patients suffering from a disease for which there is no satisfactory authorised alternative therapy, Article 83 of Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use\(^\text{43}\), establishes that the CHMP can adopt opinions on the conditions for use and distribution of products under compassionate use and patients targeted. These provisions are intended to facilitate the use of new treatment options under development. Such usage is particularly pertinent in the field of rare diseases, where the lack of existing treatments and the chronic nature of many disorders can be critical for patients.

While the implementation of compassionate use falls within the competence of each Member State, Article 83 of Regulation (EC) No 726/2004 complements national legislation and provides for an option of adoption by the European Medicine Agency’s Committee on Human Medicinal Products (CHMP) Opinion concerning the compassionate use of a particular medicinal product. Article 83 specifically seeks to “facilitate and improve the access of patients in the EU to compassionate use programmes; favour a common approach regarding the conditions of use, distribution and the patients targeted for the compassionate use of unauthorised new medicinal products; and increase transparency between member states in terms of treatment availability”. While the implementation of these recommendations is not mandatory, Member States can take them into consideration when setting up compassionate use programmes.


CHMP opinions in 2012 concerning orphan medicinal products

In 2012, the CHMP issued positive opinions for marketing authorisation applications for: Revestive (teduglutide) for the treatment of adult patients with short bowel syndrome, and Signifor (pasireotide) for the treatment of Cushing disease in patients who cannot have surgery or for whom surgery has not been successful.

Following review from its Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has also recommended marketing approval for Kalydeco (ivacaftor), an orphan-designated medicine indicated for the treatment of cystic fibrosis in patients age 6 years and older who have a G551D mutation in the cystic fibrosis transmembrane regulator (CFTR) gene. The CHMP reviewed Kalydeco in 150 days under the EMA’s accelerated assessment scheme, a mechanism created to speed up access to new medicines. Kalydeco, from Vertex Pharmaceuticals Ltd (UK), is the first treatment that targets the underlying mechanism of the disease, by restoring the mutated CFTR protein function. Other existing therapies for cystic fibrosis address the consequences of the disease, rather than the cause.

The CHMP also gave a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Volibris (ambrisentan) (Glaxo Group Ltd). The CHMP adopted a new contraindication for idiopathic pulmonary fibrosis with or without secondary pulmonary hypertension.

4. EMA activities in the field of clinical trials

EudraCT Database

A European database – EudraCT44 – contains all ongoing or completed interventional clinical trials of medicinal products falling within the scope of “Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use” (known more commonly as the “Clinical Trials Directive”45, i.e. with at least one investigator site in the EU (including the European Economic Area) and commencing after implementation of the Directive 2001/20/EC by the Member States. This database, available from March 2011, gives the competent authorities of the Member States, EMA and the Commission the necessary information to communicate on clinical trials and to maintain oversight of clinical trials and IMP development. This provides for enhanced protection of clinical trial subjects and patients receiving IMPs. Paediatric clinical trials with investigator sites inside the EEA or which form part of a Paediatric Investigation Plan (PIP)46, but that are conducted in third countries, are included (paediatric clinical trials with sites in the EU/EEA are already available). Following the guidelines published by the European Commission, all trials in the register have been authorised by the national medicine regulatory authority and have obtained a positive opinion from the ethics committee for clinical trials in the Member State concerned. Furthermore, clinical trials that include the paediatric population and have received a negative ethics committee opinion are being made public. Phase I clinical trials in adults will not be publicly available unless they form part of a PIP. The Clinical Trials Register contains historical data (all eligible trials contained in the EudraCT since its establishment in May 2004) and will contain all future trials recorded in the EudraCT.

Public access does not currently extend to data concerning trial results. The guideline relating to the posting and publication of result-related information in EudraCT has been published by the European Commission, in accordance with Article 57(2) of Regulation (EC) No 726/2004 and Article 41 of Regulation (EC) No 1901/2006 and their implementing guidelines 2008/C168/02 and 2009/C28/01. This guideline covers the sharing of result-related information in the public domain. Additionally, the technical guidance on the format of the fields provides a visual representation of the clinical trial results data that are required to be captured by EudraCT. At present, no result-related data is uploaded in EudraCT, but this will change with the release of EudraCT v9, later in 2013. After this date, clinical trial result fields identified as public will be available to users of the EU Clinical Trials Register.

44 https://eudract.ema.europa.eu/
The Clinical Trials Register does not provide data for non-interventional studies (observational, et al) for authorised products. Such data can be found via the website of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

**EMA-NIH collaboration to harmonise clinical trial register data sets**

The EMA is working with the National Institutes of Health in the USA, which manages the ClinicalTrials.gov registry of federally and privately supported clinical trials conducted in the United States and around the world as well as the Health Level 7 - Clinical Trial Registration and Results project on the harmonisation of data sets submitted by the sponsor as clinical trial registers, as well as the World Health Organization. Such harmonisation is particularly welcomed by the rare disease community, which already faces the challenges of scattered patient populations and expertise.

**Reflection paper on ethical and good clinical practice considerations for trials in third countries (2010)**

There are a significant number of clinical studies that recruit patients from several regions – including countries outside the European Economic Area – for products that will be submitted for marketing authorisation within the EU. The European Medicines Agency issued a reflection paper in 2010 considering ethical and good clinical practice aspects for such trials conducted in third countries. The paper, open for consultation until 30 September 2010, sought to ensure that so-called third country trials (countries beyond the European Economic Area) are conducted in accordance with existing principles of good clinical practice and ethical requirements. Such considerations are relevant to rare disease clinical trials, which, due to sparse and scattered patient populations, may indeed involve third country participation. For this population, post-trial treatment access is a particularly pertinent topic, especially for the often-expensive orphan medicinal products.

**Workshop on clinical trial data and transparency (22 November 2012)**

The European Medicines Agency (EMA) announced in 2012 that it will proactively publish clinical trial data and enable access to full data sets by interested parties. As there are a number of practical and policy issues that need addressing before complex data sets can be made available, a workshop was held on 22 November 2012 to discuss topics relating to this evolution. The workshop seeks to elicit the views and concerns from a broad range of institutions, groups and individuals in order to help the Agency define the modalities of proactive access to clinical trial data. A report was published after the workshops which presents the debate that was at the heart of the clinical-trial transparency event, and also outlines the Agency’s action plan with regard to access to clinical-trial data.

## 5. EMA activities in the field of advanced therapies

**EMA scientific committee for advanced therapy products (CAT)**

The EMA announced at the start of 2009 the formation of the Committee for Advanced Therapies (CAT) – the EMA’s sixth scientific committee. Created following new European Union legislation concerning the regulation of advanced-therapy medicinal products (Regulation (EC) 1394/2007), the CAT met for the first time on 15 January 2009. Three types of advanced therapy products defined in the EU legislation: gene therapy products, somatic cell therapy products and tissue engineered products. Such developments offer great potential for the treatment of rare diseases. The CAT has to “prepare a draft opinion on each advanced-therapy medicinal product (ATMP) submitted to the EMA for evaluation as part of a marketing-authorisation application, prior to the adoption of a final opinion by the Committee for Medicinal Products for Human Use (CHMP)” which will be submitted to the European Commission for decision. The experts making up the CAT also offer scientific advice as requested.

---

47 http://www.encepp.eu/
48 http://clinicaltrials.gov/
49 http://www.hl7.org/index.cfm?ref=nav
52 http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000266.jsp&mid=menus/about_us/about_us.jsp&mid=WCOb01ac05800292a48&enablend=true
Fourteen orphan products have been classified as ATMPs since the CAT was created. ATMP classification allows companies to verify whether the product they are developing meets the definition of an advanced therapy product and can benefit from the new regulatory pathway for these products. Companies developing advanced therapy medicinal products can obtain reductions in certain EMA fees including: “65% for a request for scientific advice (90% for small and medium-sized companies); and 50% for an application for a marketing authorisation, in cases where the applicant is a hospital or small/medium-sized company and can prove that its product is of a particular public-health interest”. The European Medicines Agency and its Committee for Advanced Therapies issued in April 2010 a statement54 of concern over the practice of offering unregulated stem cell products to patients for a variety of disorders - including rare conditions. While such treatments are available under limited, strictly controlled circumstances - including clinical studies, compassionate use programmes, and hospital exemption - the use of such products outside these circumstances could be harmful. The statement reminds the public that no stem-cell product has been authorised by the EMA in the European Union to date.

The European Medicine Agency’s Committee for Advanced Therapies (CAT) and the CAT Scientific-Secretariat contributed an opinion piece to Nature Reviews Drug Discovery in March 201055 in which the authors demonstrate the complexity involved with the burgeoning field of advanced therapy medicinal products (ATMP), encompassing gene therapy products, somatic cell therapy products and tissue-engineered products. Working within the regulatory parameters established under Regulation (EC) No 1394/2007, the CAT illustrates some of the complex issues inherent in both the development and the evaluation of ATMPs. As the authors point out, “Many ATMPs will be developed for rare diseases. At the EMA, the Committee for Orphan Medicinal Products (COMP) is responsible for reviewing applications seeking orphan medicinal product designation for products that diagnose, prevent or treat life-threatening or serious conditions that affect less than 5 in 10,000 persons in the European Union. The CAT considers it important that there is an active and early link with the COMP for exchange of information on orphan ATMPs, which may qualify for orphan designation, and initial discussions have already commenced. Some of the CAT members were formerly members of the COMP, so there is already a clear understanding of the needs of orphan drugs in the CAT”. The article underscores the regulatory advice that the EMA and CAT offer to drug developers stepping into this promising new field of drug development.

An Editorial article appearing in Molecular Therapy in March 2012 recalled the recent rejection of approval for Glybera (alipogene tiparvovec) by the EMA despite the approval by the CAT. In the case of Glybera, an AAV vector engineered to deliver a lipoprotein lipase cDNA to the muscle for the treatment of the rare disease lipoprotein lipase deficiency, the CHMP rejected the application despite the positive opinion of the CAT. The controversy involves the generation of statistically significant data in a small number of trial subjects, calling into question the long-term efficacy of Glybera. The Editorial article calls for clarification of the relationship between the CAT and the CHMP and for “greater emphasis” on the CAT opinion, citing the “very specific understanding of gene and cell therapy products” that the ATMPs require.

The European Medicines Agency’s Committee for Advanced Therapies (CAT) tested in 2010 its new certification system56 created to facilitate the process of advanced therapy product development amongst small and medium sized enterprises (SMEs). The CAT’s new certification procedure does not guarantee a marketing authorisation, but it sends a signal to potential investors that a sponsor is on the right track in terms of product development. An EMA press release elaborates that the certificate procedure, delineated in Commission Regulation (EC) No 668/200957 “…foresees that an SME submits to the Agency data on the quality and where available non-clinical data generated with an ATMP from an early stage of development. The CAT carries out a scientific evaluation of these data and may recommend the issuing of a certificate confirming to what extent the data generated so far comply with the review standards that would be applied for the evaluation of a marketing authorisation application”. This first certification opinion has been issued for a suspension of 5-50 107 mononuclear cells in 1 ml X-Vivo-10 medium containing 20 % autologous serum, indicated for acute myocardial infarction and chronic ischaemic heart disease.

The CAT released its Work Programme for 2010-2015 in 201058 with the overarching goal of bringing more advanced therapy products to the market. Measures, some of which are already underway, include “training and early dialogue” with relevant stakeholders and an examination of the existing regulatory

framework with an eye to making it “...more accessible for small and medium-sized enterprises, academia, patient groups, hospitals, charity foundations and trusts developing ATMPs”.

Reflection paper on the classification of advanced-therapy medicines (2012)
The European Medicines Agency (EMA) released a reflection paper on the classification of advanced-therapy medicines for public consultation. The paper clarifies the legal basis for the classification of medicines as advanced therapies and provides information on how these medicines are classified as gene therapy, somatic-cell therapy, tissue-engineered or combined medicines. The paper additionally discusses the information required for application for classification. Within the EMA, the Committee for Advanced Therapies is responsible for issuing opinions on whether a medicine should be classified as an advanced therapy. The reflection paper was open for comments until 31 July 2012.

6. EMA activities in the field of medicinal products for paediatric use

Paediatric Committee (PDCO)
The main responsibility of the Paediatric Committee (PDCO) at the EMA, established after the introduction of Regulation (EC) N° 1901/2006, is to assess the content of proposed paediatric investigation plans and adopt opinions on them in accordance with Regulation (EC) 1901/2006 as amended. This includes the assessment of applications for paediatric investigation plans with a full or partial waiver and assessment of applications for paediatric investigation plans with deferrals. The PDCO is not responsible for the evaluation of marketing-authorisation applications for medicinal products for paediatric use. This remains fully within the remit of the Committee for Medicinal Products for Human Use (CHMP). However, the CHMP or any other competent authority may request the PDCO to prepare an opinion on the quality, safety and efficacy of a medicinal product for use in the paediatric population if these data have been generated in accordance with an agreed paediatric investigation plan.

The Paediatric Committee (PDCO) is developing an inventory process aiming to identify areas in which further research and development specific to paediatric medicinal products are needed. Such an inventory could assist industry in identifying opportunities, provide a source of information for healthcare professionals and patients, and aid various PDCO assessment processes. The first inventory, in the area of cardiovascular medicines for use in children, was released for public consultation in 2012.

European Network of Paediatric Research – Enpr-EMA
The European Medicines Agency (EMA) announced in 2011 the publication of the first membership list of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Established to build a high-level network of existing research networks, investigators and centres with recognised expertise in performing clinical studies in children, the Enpr-EMA seeks to facilitate high-quality ethical research on medicines for use in children through networking and stakeholder collaboration with members from both within and outside the European Union as part of the EMA’s accordance with European Paediatric Regulation (EC) No 1901/2006. Enpr-EMA’s also aims to: coordinate studies relating to paediatric medicines and avoid unnecessary testing in children; build up scientific and administrative competence at a European level; help with the recruitment of patients for clinical trials; and promote European Commission framework programme applications. Enpr-EMA does not perform clinical trials or fund studies or research or decide on areas for paediatric research, as this is the responsibility of Member States, the European Commission or each individual network. The European Medicines Agency is responsible for ensuring collaboration within the network. The Enpr-EMA membership list was compiled following a call for expressions of interest in 2010. Some 32 networks and centres have thus far applied for membership. Of these, 16 networks and centres have become...

485c1
62 http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/q_and_a/q_and_a_detail_000108.jsp&mid=WCOb01ac0582b9f0f
members of Enpr-EMA. A second category of networks has been established for those “... undergoing clarification before membership of Enpr-EMA”. Networks grouped into a third category do not currently qualify for membership.

Database of clinical studies involving children available via the EMA (2011)
In 2011 the European Medicines Agency made available a database\(^6\) housing information on clinical studies of medicines authorised in the European Union that involved paediatric populations and were completed prior to the 2007 Paediatric Regulation came into effect. Via the Article 45 Paediatric Studies Database, it is possible to access information including the name and goal of the study, the medicinal product involved, and data on the patients, including age. Some trial outcomes are also available. The database is part of a global aim of the Agency to enhance transparency. The Agency is also specifically focused on improving information on medicinal products for paediatric populations.

7. Other EMA activities and initiatives relevant to rare diseases and orphan medicinal products

ENCePP E-Register of Studies (2010)
The European Medicines Agency (EMA) launched in 2010 the ENCePP E-Register of Studies, a publicly available electronic register developed with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)\(^6\) allowing users to consult the pharmaco-epidemiological and pharmacovigilance studies that are undertaken by academic centres and other research organisations. The E-Register offers a database resource of information on the safety and effectiveness of medicinal products. An added dividend of the E-Register is the contribution to the reduction of publication bias by “...handling both positive and negative study results in the same manner and promote exchange of information, thereby facilitating collaboration within the scientific community and preventing unnecessary duplication of research”. While the registration of a study in E-Register is completely voluntary, studies applying for the ‘ENCePP Studies’ seal that is “awarded to wholly or partially EU-based, benefit/risk studies that are carried out in compliance with the ENCePP Code of Conduct for independence and transparency and the ENCePP Checklist of Methodological Research Standards” need to register before they commence.

EMA Public Register for SMEs (2010)
The European Medicines Agency launched in 2010 a public register\(^6\) for small-and medium-sized enterprises (SMEs) that “aims at facilitating and promoting interaction amongst SMEs” by furnishing data, including contact information, areas of activity and number of employees, for SMEs registered with the agency. A second phase of the registry, available from the end of March 2011, will provide further details, including pipelines and product profiles. The new registry is part of a larger initiative to enhance transparency. It also reflects an ongoing effort of the EMA to support SMEs. The agency’s SME Office, established in 2005, encourages smaller European companies developing innovative new medicines, which are particularly promising to the field of rare diseases, by providing incentives and assistance, such as regulatory assistance, aid with translations, fee reductions, exemptions, and deferrals. The SME Office was the recipient of a 2010 European Mediscience Award for “Most significant contribution to the mediscience sector”.

EMA guidance for stem cell-based medicines (2011)
The European Medicines Agency (EMA) has issued a reflection paper\(^6\) on stem cell-based medicines that encompasses the different types of stem cells used in medicines, and addresses considerations for the development of stem cell-based medicines. In particular, the document “stresses the fact that companies developing medicines including stem cells need to pay close attention to the way the medicines are manufactured, to make sure that the final medicine is as consistent and reproducible as possible”. The reflection paper also offers consideration for pre-clinical and clinical testing. Adopted by the EMA’s Committee

---

\(^6\) http://art45-paediatric-studies.ema.europa.eu/clinicaltrials/
\(^6\) http://www.encepp.eu/encepp/studiesDatabase.jsp
\(^6\) http://fmapps.emea.europa.eu/SME/
for Advanced Therapies in January 2011, the reflection paper was open for public consultation in 2010 and was discussed at a public workshop last May 2010. Stem cell-based medicines could potentially be used in the treatment of many rare diseases.

**Good manufacturing practice database expands access to all Member States (2011)**

EudraGMP is the Community database on manufacturing and import authorisations and Good Manufacturing Practice (GMP) certificates launched by the European Medicines Agency in April 2007. In July 2009 GMP non-compliance of manufacturers was added. Now a new version of the database has been developed that offers public access to information on manufacturing inspection by regulatory authorities from all the European Economic Area countries, including all the EU Member States, Iceland, Liechtenstein and Norway. The move represents a global effort of the EMA to increase transparency. According to a press release, the wider access will, “...improve the sharing of information between regulators and industry; aid the coordination of activities related to manufacturing authorisations and GMP certificates between regulatory agencies in different European countries; eliminate the need for industry to submit applications in paper form; and facilitate the sharing of information on the outcome of inspections in the EU with regulatory authorities elsewhere in the world”. The increased access is particularly welcome to the fields of rare diseases and orphan medicinal products, which depend upon the coordination and sharing of information and activities.

**Public website for reports of adverse effects (2012)**

The European Medicines Agency (EMA) launched in 2012 a public website housing reports of adverse effects suspected in medicinal products authorised in the European Economic Area (EEA). The reports originate from national medicines regulatory authorities and the pharmaceutical companies that hold marketing authorisations for the medicines and are extracted from EudraVigilance, the European Union medicinal product safety database. The website launch is in compliance with EudraVigilance Access Policy, developed to improve public health by supporting the safety-monitoring of medicines and increasing the EMA’s level of transparency. According to a press release, the new website houses data on some 650 medicinal products, and gathers various incidents on a given product into one report. The information can be viewed by various features, including age, gender, the nature of the adverse effect, and outcome. There is also information provided on how to report a suspected adverse reaction to a medicine. The website is available in all 23 EU languages.

**Pilot for electronic application forms for submission of centralised marketing authorisation applications (2012)**

The European Medicines Agency (EMA) has launched a four-month pilot phase of electronic application forms for the submission of centralised marketing authorisation applications. The pilot will allow sponsors to use an interactive PDF form for initial marketing authorisation applications for human medicines as well as variation and renewal applications for human and veterinary medicines. The pilot moves forward the EMA’s progression toward the standard use of electronic applications.

**Public consultation on a revision of the guideline for the evaluation of human anticancer medicines (2012)**

The European Medicines Agency has opened a public consultation on the revised guideline on the evaluation of human anticancer medicines. The guideline seeks to provide guidance on all stages of clinical drug development for the treatment of malignancies, including rare cancers and paediatric cancers, all of which are rare. The guideline revision emphasises exploratory studies to properly define the most appropriate target population as well as the role of biomarkers. Also new, the guideline incorporates disease-specific guidance. Comments on the reflection paper were open until 31 May 2012.

**Guideline on use of pharmacogenetics in evaluating pharmacokinetics of medicines (2012)**

Following a period of public consultation and the consequent adoption by the Committee for Medicinal Products for Human Use, the *Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products* has now been published by the European Medicines Agency. This guideline elaborates requirements and recommendations when pharmacogenetic studies should be performed; how these studies should be designed and carried out; how the clinical impact of genetic differences between

---

patients should be evaluated; how dosing or treatment recommendations for genetic subpopulations should be studied; consequences for treatment recommendations and labelling; and the impact of interactions between medicines and of impaired or immature organ function. Companies applying for marketing authorisation should follow the guideline from 1 August 2012.

8. International cooperation between regulators in the field of orphan medicinal products

The European Medicines Agency has been supporting the development of international collaboration between regulators. In the field of orphan medicinal products the Agency has established regular contacts with the Office for Orphan Products Development of the FDA (OOPD FDA) and the Japanese authorities (PMDA and MHLW). These contacts are aimed at establishing contacts that facilitate exchange of information and discussion of regulatory issues in order to respond to the globalization of product development and research.

The COMP has established an active international cooperation, which will be expanded in 2013. In 2008, the Committee started collaboration with the United States Food and Drug Administration (FDA), allowing applications for orphan-drug designations to be submitted in parallel to the two agencies. The parallel submission process helps rationalise the development of orphan medicines by facilitating access to parallel scientific advice (protocol assistance) from the two regulatory authorities. Based on the success of this collaboration, which led to 62% of applications submitted in parallel in the EU and the FDA in 2012, last year the COMP began to collaborate with the Japanese regulatory authorities. An increase in the number of Japanese orphan-drug designations with prior European designations was observed in 2012. A dialogue with Health Canada has been established and a closer collaboration with this country is anticipated in 2013.

EU-USA collaboration in the field of orphan medicinal products

The European Union (EU), including the European Commission and the European Medicines Agency, has had confidentiality arrangements with the United States Food and Drug Administration (FDA) since September 2003. Under the agreement, both the EMA and the FDA can exchange confidential information pertaining to scientific advice, orphan medicinal product designation, paediatric development, good manufacturing practice and good clinical practice inspection planning and reports, marketing authorisation procedures and subsequent changes to the marketing authorisations together with post-marketing surveillance as part of their regulatory and scientific processes. This includes information on advance drafts of legislation and regulatory guidance documents, as well as non-public information related to ensuring the quality, safety and efficacy of medicinal products for human and veterinary use. The agreement extends to medicines that are authorised at the national level by individual EU Member States, as well as those undergoing the centralised process. The extension is considered good news by the rare disease community, which counts on international cooperation to bring treatments to patients. The confidentiality agreements between the EU and the FDA were extended in 2005 and again in 2010. They are now effective for an indefinite period without the need for further renewal.

As part of the ongoing confidentiality agreement between the European Commission, the European Medicines Agency, and the US Food and Drug Administration, a new initiative was launched for an 18 month pilot phase on 1 September 2009. The Good Clinical Practice Initiative - a reflection of both the increasing globalisation of clinical studies and limited inspection resources - defines its objectives as “the sharing of information on inspection planning, policy and outcomes and the conduct of collaborative inspections”. The small patient populations typically available for rare disease medicinal product trials dispose such trials to international participation. By harmonising inspection procedures, the new initiative is expected to play a key role in ensuring that trials are conducted under safe, ethical, and uniform conditions. One of the principle objectives for the pilot phase of the initiative includes the exchange of Good Clinical Practice-related information “contained in applications for scientific advice, orphan medicines designation, paediatric investigative plans, marketing authorization or post-authorization activities of significant public health interest". In a press release, the FDA and EMA announced that they “are looking to partner with


applicants/sponsors who are willing to volunteer during the pilot phase of the initiative to engage in dialogue and planning of joint inspections involving applications that are anticipated to be submitted fairly simultaneously to both regulatory agencies within the next 12 months”.

The interaction between the Agency and the FDA has been supported further by the transatlantic administrative simplification action plan. This plan was set up in November 2007 by the European Commission and the FDA, with the collaboration of the Agency and the Heads of Medicines Agencies. The plan aims to remove administrative burden in the interaction between medicines regulators in Europe and in the USA, while maintaining or increasing levels of public-health protection. In addition, since 2009, the FDA has seconded a permanent representative to the Agency’s office in London. Since early 2010, this has been mirrored by the Agency seconding its own representative to the FDA’s offices.

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) moved their collaborative effort another step forward in late February 2010 with the introduction of an agreement that permits one single annual report to be submitted for orphan products designated in both the EU and the USA. Prior to this, sponsors with designations in both places were required to submit two separate reports detailing the progress of drug development, including “a review and status of ongoing clinical studies, a description of the investigation plan for the coming year, any anticipated or current problems in the process, difficulties in testing, and any potential changes that may impact the product’s designation as an orphan product.” Each regulatory body will continue to conduct its own assessment of the reports filed in order to appraise whether information satisfies the legal and scientific requirements of each agency. The option of submitting a single annual report to both agencies benefits sponsors by reducing the duplication of efforts.

As a result of the aforementioned initiatives, currently more that 80% of the applications for orphan designation use the EMA/FDA common application form which is facilitating parallel submission and decreasing the administrative burden for sponsors.

Other initiatives include a pilot programme on joint good-manufacturing-practice (GMP) inspections for manufacturers of medicinal products in August 2010, and a three-year pilot was announced for April 2011, which will allow the parallel evaluation of ‘quality by design’ aspects of applications submitted to the Agency and the FDA at the same time. Quality by design is an enhanced systematic and science-based approach to the development and manufacture of medicines that ensures better quality of medicines.

In 2011 the FDA and the EMA hosted in London the first joint workshop on applications for orphan designation, marking the first occasion in which sponsors have been able to discuss in real time applications for designation with both Regulatory Authorities. In 2012 the two regulatory agencies held a second workshop in Washington. The workshop provided information about the EMA and FDA Orphan Drug Designation programs, the FDA Humanitarian Use Device (HUD) Designation program, the FDA Orphan Products Grants program, and European Union (EU) rare disease research programs to over 200 participants from over 11 countries representing pharmaceutical, biotechnology, device companies, academia, drug and device regulators. The workshop was held in partnership with the European Organisation for Rare Diseases (EURORDIS), Genetic Alliance and the National Organization for Rare Disorders (NORD).

The FDA published a report of their activity in the realm of innovative medicines in 2011. Orphan drugs come out well making up almost a third of the 35 innovative medicinal products that were approved by the FDA in fiscal year 2011. Moreover, the FDA approved nearly half (16) of the innovative drugs under the agency’s “priority review” programme. This scheme accelerates the approval process for drugs that may offer major advances in treatment. The FDA defines innovative medicines as “new molecular entities”, novel chemical structures, including biological products, which have never been approved before to treat any disease, and often represent the most innovative drugs entering the market. Ten of the innovative products approved in fiscal year 2011 have orphan indications.

In fiscal year 2012, FDA continued to bring innovative drugs to patients in the United States quickly and efficiently, while ensuring that medicines are safe and effective. Of the 35 novel drugs approved in 2012, nine concerned orphan diseases, continuing FDA’s commitment to approve drugs for patients with rare conditions. Again, FDA expedited the review and approval of over half of these innovative medicines by using its several review authorities for important new drugs, including Fast Track, Priority Review, and Accelerated Approval.

**Confidentiality agreement with Japan (2012)**

The European Medicines Agency and the European Commission announced in 2012 the extension of their confidentiality arrangement with the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency of Japan, established in 2007, for another year. Under the arrangement, advance drafts of legislation and regulatory guidance documents, scientific advice on medicine development, assessments of applications for marketing authorisations and information concerning the safety of marketed medicines may be exchanged between the two agencies. This is welcome news for the rare disease and orphan drug community, which is striving to reduce duplication of effort and encourage cooperation in the field.

---

B. OTHER EUROPEAN RARE DISEASE ACTIVITIES


The Pharmaceutical Forum\(^{78}\) was set up in 2005 as a three year process by Vice-President Verheugen and Commissioner Kyprianou, in order to find relevant solutions to public health considerations regarding pharmaceuticals, while ensuring the competitiveness of the industry and the sustainability of the national health-care systems. This high-level ministerial platform for discussion between Member States, EU institutions, industry, healthcare professionals, patients and insurance funds focused its work on three main topics: information to patients on diseases and treatment options; pricing and reimbursement policy and relative effectiveness. The last Ministerial meeting, on 2 October 2008, concluded the three year exercise with the adoption of the final report gathering Final Conclusions and Recommendations. It also included all technical documents and projects developed by the three working groups to support implementing actions addressed to the European Commission, Member States and interested stakeholders.

In that framework, the members of the working group on pricing and reimbursement decided to examine how access to orphan medicines may be improved. Indeed, Orphan medicines amplify the common tensions in the field of pricing and reimbursement: assessing and rewarding innovation is difficult, budget optimisation is challenged and access for patients is limited in several countries. In spite of many policy initiatives increasing the number of newly developed orphan medicines, many of these are not available for all EU citizens.

Based on the paper “Improving access to orphan medicines for all affected EU citizens”\(^{79}\) developed by its members, The High Level Pharmaceutical Forum recommended the following\(^{80}\): Member State authorities, stakeholders and the Commission should strengthen their efforts to ensure access to orphan medicines in all EU Member States. They are therefore called upon to take up the appropriate ideas developed in the Working Group Pricing regarding i) early dialogue on research and development, ii) exchange of knowledge on the scientific assessment of the clinical added value, iii) specific pricing and reimbursement mechanisms and iv) increased awareness on orphan diseases.

2. E-Rare

E-Rare, ERA-Net for Research Programmes on Rare Diseases, which was launched in its first phase in 2006 and in its second phase in 2010 (E-Rare-2; 2010-2014), is currently funded under the ERA-Net Scheme in FP7 by the European Commission. The main goal of E-Rare is to build the foundation for a transnational research programme on rare diseases.

The E-Rare Consortium gathers a group of sixteen research funding organisations from Austria, Belgium, France, Greece, Germany, Hungary, Italy, Israel, Portugal, Spain, the Netherlands and Turkey (and Poland, as an observer), which are cooperating under this single umbrella to maximise the added value of coordinated transnational research funding in the field of rare diseases.

Since 2007, the E-Rare Consortium has launched 4 joint transnational calls (2007, 2009, 2011 and 2012) for collaborative multidisciplinary research projects open for any rare disease (except rare cancers and rare infectious diseases), with a wide range of possible topics and approaches. A total of 475 multinational applications involving more than 1900 research groups from European and associated countries were submitted. The participating national funding agencies from 6 (2007) and 10 (2009, 2011, 2012) countries provided funding for 53 consortia for a total of €37.5 million Euros. Importantly, the 4th Joint Transnational Call (2012) was dedicated specifically to “European Research Projects on Rare Diseases driven by Young Investigators”. The aim was to provide young, independent investigators the opportunity of building

\(^{78}\) http://ec.europa.eu/pharmaforum/index_en.htm

\(^{79}\) http://ec.europa.eu/pharmaforum/docs/pricing_orphans_en.pdf

transnational collaborations in the field of rare disease research. Following the call, 11 consortia were funded for a total of around €9 million.

In December 2012, E-Rare launched its 5th Joint Transnational Call (JTC 2013) open to participants in 14 countries including Canada, Hungary, Romania and Switzerland, joining the E-Rare call for the first time.

The overwhelming response to the E-Rare joint calls demonstrates the demand and the potential of the rare disease research community to engage in collaborations with complementary expertise.

It is now recognised that E-Rare has become one of the major contributors to transnational rare diseases research funding. To continue and expand its activities in accelerating the development of new diagnostics and therapeutics for patients suffering from rare diseases the “E-Rare Group of Funders” (FWF, Austria; FNRS, Belgium; FWO, Belgium; ANR, France; BMBF, Germany; GSRT, Greece; ISS, Italy; CSO/MOH, Israel; FCT, Portugal; ISCIII, Spain; ZonMw, The Netherlands and TUBITAK, Turkey) recently joined (in September 2012) the International Rare Disease Research Consortium (IRDiRC).

3. Clinical genetics as a medical speciality

The European Union of Medical Specialists (UEMS), a non-profit organisation founded in 1958 to determine high quality standards harmonising specialist training for European physicians, represents some 1.5 million European medical specialists in 38 specialist sections throughout 35 national member associations. In April 2009, the UEMS Council adopted the text entitled Description of Clinical Genetics as a Medical Specialty in EU: Aims and objectives for specialist training. The document, which defines educational goals for a specialisation in genetic medicine, has already been endorsed by the European Society of Human Genetics, the UEMS Multidisciplinary Joint Committee for Clinical Genetics, and the UEMS Specialist Sections & European Boards. This is good news for rare disease patients in countries where clinical genetics is not yet recognised: Belgium, Greece and Spain.


(7) Medical genetics is a specialty that responds to the rapid development of knowledge in the field of genetics and its implication in numerous specialised fields, such as oncology, foetal medicine, paediatrics, chronic diseases. Medical genetics plays a growing role in screening and in the prevention of numerous pathologies. Specialist medical training in medical genetics is not listed in point 5.1.3 of Annex V to Directive 2005/36/EC. However, it has developed into a separate and distinct specialist medical training in more than two fifths of the Member States, which justifies its inclusion into point 5.1.3 of Annex V to Directive 2005/36/EC.

(8) In order to ensure a sufficiently high level of specialist medical training, the minimum period of training required for the medical specialty of medical genetics to be automatically recognised should be four years.

Recognition of the speciality is critical both for the training of professionals and the organisation of related services.

4. Resolution on pharmacy prepared medicinal products adopted by the Council of Europe (2011)

Resolution CM/ResAP(2011) on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients was adopted by the Committee of Ministers of the Council of Europe on 19 January 2011. Special needs can arise from factors such as patient age, medical condition (such as rare diseases), individual disposition or environmental factors. The resolutions help to harmonise the preparation of medicinal products in community and hospital pharmacies throughout Europe and address the added value of pharmacy preparations; the responsibilities of health-care professionals; the preparation

---

81 http://admin.uems.net/uploadedfiles/1305.pdf
83 https://wcd.coe.int/wcd/ViewDoc.jsp?Ref=CM/ResAP%282011%291&Language=lanEnglish&Ver=original&BackColorInternet=DBDCF2&BackColorIntranet=FDC864&BacColorLogged=FDC864
process; the product dossier; labelling; the reconstitution of medicinal products in health-care establishments; and authorisation for pharmacies or licences for companies making preparations for pharmacies.

5. International Rare Disease Events in 2012

Rare Disease Day 2012 (29 February 2012)
The Fifth edition of the annual Rare Disease Day 2012, organised by EURORDIS, was held on 29 February 2012. Rare Disease Day 2012 included 63 countries (up from 55 in 2011, 46 in 2010, 30 in 2009 and 18 the first year); first-time countries this year included Costa Rica, Chile, Macedonia, Malta, Pakistan, Uruguay, and Venezuela. In 2012, over 300 "Friends of Rare Disease Day" signed up on the Rare Disease Day (RDD) website including the French Ministry of Health and other luminaries such as Harvard Medical School, the Slovenian Ministry of Health, members of the biopharmaceutical industry, numerous patient groups and individuals involved with patients, rare disease research entities, and others.

The official Rare Disease Day (RDD) website, maintained by EURORDIS, received almost 40,000 visits from some in the weeks leading up to the day. The response to social media was strong: the RDD Facebook page received over 13,000 "likes" and thousands of "Tweets" were sent via Twitter. Over 350 photo stories were uploaded to the site and the special Rare Disease Day video has been viewed over 100,000 times. The media played a key role as print, radio and television news sources around the world reported on the happenings, heightening exposure to the rare disease cause significantly.

In 2012, Rare Disease Day put the spotlight on "Solidarity" a value that characterises the rare disease patient movement across diseases and national boundaries. The theme also served to focus on the importance and the need for collaboration and mutual support in an area where patients are rare, expertise is scarce and people affected face similar challenges. At the European level, Rare Disease Day will sought to highlight rare diseases as a model of EU solidarity in today’s crisis-stricken Europe. In line with this initiative, EURORDIS organised a symposium with the European Commission, in Brussels on 29 February 2012, to showcase the successes achieved over the last decade and to discuss the way forward. The European Symposium 'Rare Diseases a model of EU Solidarity'. The meeting aimed to demonstrating the value of the EU-wide approach in the area of rare diseases – show it has a positive impact on the health of all EU citizens and can generate a good return to investment, in addition to being a model that is being emulated outside of the EU. Attendees included patients and patient representatives, researchers, health professionals, members of the EU Committee of Experts on Rare Diseases, European Parliamentarians, high-level officials of the European Medicines Agency and the European Commission, as well as representatives of the pharmaceutical and biotech industry.

In addition, EURORDIS held a gala on the evening of the 29 February 2012 in Brussels, presenting awards for excellence and leading work in the field of rare diseases. These prestigious awards are judged by the EURORDIS Board of Directors based on over 100 nominations received from EURORDIS members, volunteers and staff. The EURORDIS Awards are designed to recognise the outstanding commitment and achievements of patients' advocacy groups, volunteers, scientists, companies, media and policy makers who have contributed directly or indirectly to reducing the impact of rare diseases on people's lives.

The EUCERD fully endorses the International Rare Disease Day campaign to raise awareness for the health inequities in the field – and particularly supports the promotion of rare diseases in the Third EU Public Health Programme (2014 to 2020) - and will continue working hard to level the playing field for all the rare disease stakeholders out there.

EC Joint Research Centre workshop on the Genetic Testing Offer in Europe – Ispra, 19-20 November 2012
The EC's Joint Research Centre organised, in collaboration with the EUCERD and Eurogentest, an expert workshop in Ispra at the end of 2012 in order to discuss a number of areas where European cooperation could give added-value in terms of the quality of genetic services and the organisation of genetic services. The topics discussed included the organisation of quality assessment schemes, the challenge presented by next generation sequencing techniques and direct-to-consumer testing. Areas for harmonisation at European level
could be envisaged, and the outcomes of the workshop will be considered by the EC. The outcomes of the workshop will be considered by the EUCERD as a basis for a possible future EUCERD recommendation in this area.

**European Conference on Rare Diseases and Orphan Products – Brussels, 24-25 May 2012**

The sixth edition of this biennial conference drew together the rare disease and orphan drug community from across Europe and beyond to share triumphs, address problems, unstop bottlenecks, and move forward on all fronts – regulatory, research, policy, therapeutic, social. Organised by the European Organisation for Rare Diseases (Eurodis) and the DIA Europe, the ECRD was held in Brussels from 24-25 May. Over 650 participants from 45 different countries attended.

Perhaps the largest benefit of the ECRD is its capacity to galvanise stakeholders. The rich exchange between participants – researchers, health professionals, patients and patient organisations, policy makers, members of the biopharmaceutical industry, and bioinformatics specialists, breathes fresh hope and energy into the goals and struggles individual participants bring to the table. This year’s event was particularly pivotal for driving forward national rare disease plans, which the Council Recommendation on an Action in the Field of Rare Diseases urges EU Member States to create by the end of 2013. This year’s ECRD focused on several often complex issues relating to the implementation of the Council Recommendation. The organisation and development of Centres of Expertise for rare diseases was discussed at length, along with similar issues around the European Reference Networks, which still have to be defined and selected within the context of the Directive on cross-border healthcare, the adoption of which spurred discussion on how the rare disease community can best benefit from sharing knowledge and resources. While most experts agree that it is the data that must travel as much as possible, many practical questions – especially in the areas of the organisation of expertise and reimbursement – remain to be ironed out. Other topics addressed this year included Health Technology Assessment (HTA) in the EU Member States and how to develop a harmonised approach that will yield greater equity between countries while eliminating unnecessary duplication of effort. Another interesting subject involved the care of patients transitioning from paediatric to adult services. For many rare diseases, comprehensive services available for paediatric populations suddenly dry up when patients reach adulthood. Given that advances in care and treatment are allowing a longer life for many patients, this is an urgent question that needs addressing.

There were many interesting sessions offered within the context of seven distinct themes: National Plans for Rare Diseases; Centres of Expertise and European Reference Networks; Information and Public Health; Research from Bench to Bedside; Orphan Products and Rare Disease Therapies – Access; Orphan Products and Rare Disease Therapies – Regulatory; and Patients’ Empowerment. Of particular note were the opening Plenary sessions, which featured a keynote address from European Commissioner for Health and Consumer Policy, John Dalli, who set a tone of optimism by announcing that “action on rare diseases features prominently in the European Commission proposal for the new Health Programme and the new Research Programme for 2014 onwards” and that he was confident that the EU Member States would “adopt national plans on rare diseases in due time despite the difficult economic climate”.

Other notable sessions throughout the two day event included the Introduction to Centres of Expertise; How Rare Disease Research can contribute to innovation; Introduction of European Reference Networks; Making rare diseases visible for research and public health; The Big Picture of Rare Disease Research Policy; The value and specificity of the rare disease business model; Improving Care through Clinical Guidelines; EU Infrastructure & Projects in the field of rare diseases and patient registries; EU Policy Developments in the Field of Access to Orphan Drugs; Health care pathways focusing on transition from childhood to adulthood; Novel reimbursement schemes as a potential way forward; Compassionate Use Programmes; and Ways to look at HTA for Orphan Drugs and Rare Diseases.

The Executive summary report of the conference includes the main features and statistics of the Conference, the programme at a glance, a list with photos of the Programme Committee, a list of posters’ titles and authors, as well as the poster winner and descriptions of exhibiting companies.

The seventh ECRD will be held in Berlin in 2014.

**High Level Conference - EU Health Programmes: results and perspectives (2012)**

A conference was held on 3 May 2012 by the European Commission’s Directorate-General for Health and Consumers and its Executive Agency to reflect on the results and success stories from the first and second
Health Programmes. The conference was also an opportunity to share views and build consensus for the future third programme. More than 400 people have participated in the conference, including policy makers, key actors from the health sector, NGOs, Member States and European institutions, health programmes' beneficiaries, scientists and academics from EU and third countries, participating in the Health Programme.

6. Other European activities in the field of rare diseases in 2012

Council of Europe information document on genetic tests for health purposes (2012)
The Council of Europe, with the support of the European Society of Human Genetics and EuroGentest, published in 2012 an information document that aims to “provide objective information on genetic tests, their nature and potential implications of their results”. The document also presents different types of tests available, their application in the medical field and the extent and limits of the test results. The document can be consulted in a range of languages on the site of the Council of Europe.

European Academies Science Advisory Council and Federation of European Academies of Medicine recommendations on Direct-to-Consumer genetic testing (2012)
A lay account of the latest report of EASAC - the European Academies Science Advisory Council, and FEAM - the Federation of European Academies of Medicine, entitled “Direct-to-Consumer genetic testing for health-related purposes in the European Union” was published in 2012. This report details the outcomes of a Working Group set up by EASAC and FEAM to review consumer genetic services in Europe. The report proposes a “list of recommendations to policy-makers in the European Commission, European Parliament and Council of Ministers, and to Member States in which parallel action may be necessary”.

European Directory of Health Apps (2012)
The first edition of the European Directory of Health Apps was unveiled on 3 October 2012 at the European Health Forum Gastein 2012. The Directory contains information on some 200 health-related smartphone applications that assist patients with the management of their medical conditions – including several rare diseases. Published by UK-based research, publishing and consultancy group, PatientView, with a foreword from Robert Madelin, European Commission Director General for Communications Networks, Content and Technology (DG Connect), the Health Apps selected for the Directory have all been recommended by patient groups and empowered consumers. There is one App for rare diseases in general: ODDT, a crowdsourced content aggregator that collates treatment research data, primarily for scientists. There are also Apps for specific rare diseases, including haemophilia and Huntington disease, an App on Cross-Border Healthcare, and several Apps for communication disability, deafness, visual impairment, physical disability and other conditions frequently associated with rare conditions. The Directory provides a description for each App, including technical details, available languages, and reviews from related patient/consumer groups. The Directory cross-indexes Apps by name, specialisation, and language.

European Patients Academy on Therapeutic Innovation launches as an educational resource on medicinal product research and development (2012)
The European Patients' Academy on Therapeutic Innovation (EUPATI) launched in 2012 as a patient-led initiative that will develop educational material, training courses and a public Internet library to educate patient representatives and the lay public about the various processes involved in medicines development. Rare disease patient organisation stakeholders will play a prominent role in the five-year effort. Topics will include the design and conduct of clinical trials, drug safety and risk/benefit assessment, health economics, patient involvement in drug development and personalised and predictive medicine. Funded by the Innovative Medicines Initiative (IMI), EUPATI seeks to provide scientifically reliable, comprehensive information that will enable patients to serve as effective advocates and advisors in different capacities, such as working with

87 http://ec.europa.eu/health/programme/docs/eu_20120503_prog_en.pdf
89 http://www.coe.int/t/dg3/healthbioethic/Activities/07_Human_genetics_en/Brochure/default_en.asp
92 http://www.patientsacademy.eu
regulatory authorities and ethics committees. Educational resources will be produced in English, French, German, Italian, Polish, Russian and Spanish languages.

LIST OF CONTRIBUTIONS

Contributions from the European Medicines Agency:

European Medicines Agency
Jordi Linares-Garcia (Head of Orphan Medicines)

This report was compiled by Charlotte Rodwell
(Scientific Secretariat of the European Union Committee of Experts on Rare Diseases, INSERM US14, France)

93 The contributors and validators of the report have contributed information which is accurate to the best of their knowledge. However, readers should take note that the contents of this report are illustrative and not exhaustive.

94 Disclaimer: the EMA is not responsible for the completeness and correctness of the information included in this report.
SELECTED BIBLIOGRAPHY AND SOURCES

1. EUROPEAN SOURCES

WEBSITES

European Commission & EMA websites

- Rare Diseases information on the EC Public Health portal

- Public health initiatives and other institutions responsible for rare diseases on the DG Sanco

- Europe for patients: rare diseases
  http://ec.europa.eu/health-eu/europe_for_patients/rare_diseases/index_en.htm

- Eudra-CT (European Clinical Trials Database)
  https://eudract.ema.europa.eu/

- CORDIS: the gateway to European Research and development

- European Commission research and innovation
  http://ec.europa.eu/research/index.cfm?lg=en

- European Medicines Agency Committee for Orphan Medicinal Products

Other European websites

- Orphanet
  http://www.orpha.net

- OrphaNews Europe archives
  http://www.orpha.net/actor/cgi-bin/OAhome.php?Ltr=EuropaNews

- EURORDIS
  http://www.EURORDIS.org

- Eurocat
  http://www.eurocat-network.eu/

- EUROPLAN: Final National Conference Reports
  http://www.europlanproject.eu/_newsite_986987/events22.html

KEY TEXTS

Directives, Regulations, Communications, Council Decisions, Council Recommendations and other related documents


95 All websites and documents were last accessed in May 2013.


Programmes of Community Action, Work Programmes and Calls


• DG Sanco Work Plan 2012

• DG Research and Innovation FP7 Calls

• EMA Work Programme 2011

• EMA Work Programme 2012

KEY DOCUMENTS

DG Enterprise and Industry

• Inventory of Community and Member States’ incentive measures to aid the research, marketing, development
  and availability of orphan medicinal products (2005 revision)

• Final Conclusions and Recommendations of the High Level Pharmaceutical Forum (2nd October 2008)

• Initial investigation to assess the feasibility of coordinated system to access orphan medicines (Gesundheit
  Österreich GmbH, May 2011)

DG Health and Consumers

RDTF Publications

• RDTF Report – Overview of Current Centres of Reference on rare diseases in the EU – 12 September 2005

• RDTF Report: Centres of Reference for Rare Diseases in Europe – State-of-the-art in 2006 and Recommendations
  of the Rare Diseases Task Force – 1 September 2006


• RDTF Report: Health Indicators for Rare Diseases: State of the art and future directions – June 2008

• RDTF Report: How many drugs for how many patients – July 2007

• RDTF Report: Health Indicators For Rare Diseases I - Conceptual Framework And Development Of Indicators From
  Existing Sources – April 2010

EUCERD Publications

• EUCERD Report: Initiatives and Incentives in the field of rare diseases – July 2010

• EUCERD Report: Preliminary analysis of the outcomes and experiences of pilot European Reference Networks for
  rare diseases - May 2011
EUCERD Report: 2012 Report the State of the Art of Rare Disease Activities in Europe of the EUCERD - Part I: Overview of Rare Disease Activities in Europe and Key Developments in 2010 – July 2012


EUCERD Report: 2012 Report on the State of the Art of Rare Disease Activities in Europe of the EUCERD – Part V: Activities of European Member States and other European Countries in the field of rare diseases

EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States – October 2011

Recommendations of the EUCERD to the European Commission and Member States on Improving Informed Decisions Based on the Clinical Added Value of Orphan Medicinal Products (CAVOMP) Information Flow - September 2012
http://www.eucerd.eu/?post_type=document&p=1446

EUCERD Recommendations on European Reference Networks for Rare Diseases - 31 January 2013
http://www.eucerd.eu/?post_type=document&p=2207

DG Research and Innovation

International Rare Disease Research Consortium (IRDiRC) First Workshop Summary Report

International Rare Disease Research Consortium (IRDiRC) Second Workshop Summary Report

European Medicines Agency

European Medicines Agency Annual Report for 2010

COMP Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation (EMA/COMP/15893/2009)

Joint Research Centre

European Workshop on Genetic Testing Offer in Europe (November 2012)

OTHER DOCUMENTS

Orphanet Report Series: Prevalence of reported number of published cases listed by alphabetical order by disease
http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf
2. INTERNATIONAL SOURCES

WEBSITES

- International Rare Disease Research Consortium (RDiRC)
  www.irdirc.org

- Topic Advisory Group for Rare Diseases – Revision of the WHO ICD
  http://www.who.int/classifications/icd/TAGs/en/index.html

REPORTS/ARTICLES

  http://www.ohe.org/publications/recent-publications/list-by-title-20/detail/date///access-mechanisms-for-orphan-drugs-a-comparative-study-of-selected-european-countries.html


- INESSS Report: Prise en charge des maladies rares - Expériences étrangères (August 2011)

3. OTHER DOCUMENTS/SITES

- **EPPOSI**
  
  Archive of EPPOSI workshop reports in the field of rare diseases
  

- **European Conference on Rare Diseases 2012**
  
  ECRD 2012 Final Report
  

- **Rare Disease Day**
  
  [http://www.rarediseaseday.org](http://www.rarediseaseday.org)